Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other financing activities (2021 - 2025)

Akebia Therapeutics has reported Other financing activities over the past 4 years, most recently at $63000.0 for Q1 2025.

  • Quarterly Other financing activities fell 91.6% to $63000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $63000.0 through Dec 2025, down 95.05% year-over-year, with the annual reading at $63000.0 for FY2025, 95.05% down from the prior year.
  • Other financing activities was $63000.0 for Q1 2025 at Akebia Therapeutics, down from $522000.0 in the prior quarter.
  • Over five years, Other financing activities peaked at $44.8 million in Q2 2021 and troughed at $63000.0 in Q1 2025.
  • The 4-year median for Other financing activities is $750000.0 (2024), against an average of $17.2 million.
  • The largest YoY upside for Other financing activities was 91.6% in 2025 against a maximum downside of 91.6% in 2025.
  • A 4-year view of Other financing activities shows it stood at $44.8 million in 2021, then decreased by 10.68% to $40.0 million in 2022, then crashed by 98.7% to $522000.0 in 2024, then tumbled by 87.93% to $63000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other financing activities are $63000.0 (Q1 2025), $522000.0 (Q3 2024), and $750000.0 (Q1 2024).